MX2022011527A - Formulaciones de oligosacaridos de agonistas del receptor opioide kappa. - Google Patents
Formulaciones de oligosacaridos de agonistas del receptor opioide kappa.Info
- Publication number
- MX2022011527A MX2022011527A MX2022011527A MX2022011527A MX2022011527A MX 2022011527 A MX2022011527 A MX 2022011527A MX 2022011527 A MX2022011527 A MX 2022011527A MX 2022011527 A MX2022011527 A MX 2022011527A MX 2022011527 A MX2022011527 A MX 2022011527A
- Authority
- MX
- Mexico
- Prior art keywords
- opioid receptor
- kappa opioid
- oligosaccharide
- formulations
- receptor agonists
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 229920001542 oligosaccharide Polymers 0.000 title abstract 5
- 150000002482 oligosaccharides Chemical class 0.000 title abstract 5
- 102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 3
- 108020001588 κ-opioid receptors Proteins 0.000 title abstract 3
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 3
- 239000003623 enhancer Substances 0.000 abstract 3
- 239000002632 kappa opiate receptor agonist Substances 0.000 abstract 3
- 229940126470 kappa opioid receptor agonist Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención proporciona formulaciones para el suministro oral de un agente terapéutico donde la formulación comprende un agonista del receptor opioide kappa, un agente estabilizante de tipo oligosacárido y un potenciador de la absorción opcional. El agonista del receptor opioide kappa puede estar recubierto con, embebido en o mezclado con un oligosacárido tal como trehalosa. También se proporcionan cápsulas que contienen las formulaciones orales de los agonistas del receptor opioide kappa, el oligosacárido y el potenciador de la absorción de la invención. La invención proporciona además métodos de fabricación de las formulaciones y métodos para su uso para la profilaxis, inhibición y tratamiento de una variedad de enfermedades y afecciones asociadas con el receptor opioide kappa tales como dolor, prurito e inflamación. Los métodos de uso incluyen administrar al mamífero la formulación del agonista del receptor opioide kappa, oligosacárido y potenciadores de la absorción opcionales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991560P | 2020-03-18 | 2020-03-18 | |
| PCT/US2021/022878 WO2021188753A1 (en) | 2020-03-18 | 2021-03-18 | Oligosaccharide formulations of kappa opioid receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011527A true MX2022011527A (es) | 2022-11-10 |
Family
ID=77746462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011527A MX2022011527A (es) | 2020-03-18 | 2021-03-18 | Formulaciones de oligosacaridos de agonistas del receptor opioide kappa. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11986509B2 (es) |
| EP (1) | EP4121083A4 (es) |
| JP (1) | JP2023518711A (es) |
| KR (1) | KR20230002361A (es) |
| CN (1) | CN115335072A (es) |
| AU (1) | AU2021236662A1 (es) |
| BR (1) | BR112022018654A2 (es) |
| CA (1) | CA3171225A1 (es) |
| IL (1) | IL296368A (es) |
| MX (1) | MX2022011527A (es) |
| WO (1) | WO2021188753A1 (es) |
| ZA (1) | ZA202211363B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942665B (zh) * | 2023-09-21 | 2023-12-12 | 广州市朝利良生物科技有限公司 | Kappa阿片受体拮抗剂在制备抗冠状病毒药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6187330B1 (en) * | 1998-01-30 | 2001-02-13 | Scios Inc. | Controlled release delivery of peptide or protein |
| US20180078605A1 (en) * | 2006-11-10 | 2018-03-22 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for uremic pruritus in dialysis patients |
| AU2007317817B2 (en) * | 2006-11-10 | 2012-09-20 | Cara Therapeutics, Inc. | Synthetic peptide amides |
| WO2008064353A2 (en) | 2006-11-22 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | 7,8-saturated-4,5-epoxy-morphinanium analogs |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| FR2963889B1 (fr) | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
| BR112013023062B1 (pt) | 2011-03-10 | 2022-01-18 | Xeris Pharmaceuticals, Inc | Solução estável para a injeção parenteral e método de fabricação da mesma |
| AU2015258836B2 (en) | 2014-05-16 | 2020-07-16 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
| ES2916834T3 (es) | 2014-09-27 | 2022-07-06 | Sumitomo Pharma Co Ltd | Composición farmacéutica para inyección |
| WO2016163403A1 (ja) * | 2015-04-07 | 2016-10-13 | ニプロ株式会社 | 経口フィルム製剤 |
| US20190111001A1 (en) | 2016-03-30 | 2019-04-18 | University Of Maryland, Baltimore | Microparticulate system for colonic drug delivery |
| WO2017210668A1 (en) * | 2016-06-03 | 2017-12-07 | Jt Pharmaceuticals, Inc. | Sustained release compositions of kappa-opioid receptor agonist |
| AU2017307306B2 (en) * | 2016-08-05 | 2022-06-30 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| EP3558300B1 (en) * | 2016-12-21 | 2021-11-24 | Tioga Pharmaceuticals, Inc. | Solid pharmaceutical formulations of asimadoline |
| CN112739366B (zh) | 2018-09-14 | 2024-08-30 | 卡拉治疗学股份有限公司 | κ阿片受体激动剂的口服配制品 |
-
2021
- 2021-03-18 BR BR112022018654A patent/BR112022018654A2/pt not_active Application Discontinuation
- 2021-03-18 MX MX2022011527A patent/MX2022011527A/es unknown
- 2021-03-18 IL IL296368A patent/IL296368A/en unknown
- 2021-03-18 EP EP21771392.4A patent/EP4121083A4/en active Pending
- 2021-03-18 KR KR1020227034646A patent/KR20230002361A/ko active Search and Examination
- 2021-03-18 AU AU2021236662A patent/AU2021236662A1/en active Pending
- 2021-03-18 US US17/204,986 patent/US11986509B2/en active Active
- 2021-03-18 CA CA3171225A patent/CA3171225A1/en active Pending
- 2021-03-18 JP JP2022554618A patent/JP2023518711A/ja active Pending
- 2021-03-18 WO PCT/US2021/022878 patent/WO2021188753A1/en active Application Filing
- 2021-03-18 CN CN202180022064.XA patent/CN115335072A/zh active Pending
-
2022
- 2022-10-17 ZA ZA2022/11363A patent/ZA202211363B/en unknown
-
2023
- 2023-05-30 US US18/203,134 patent/US20230381265A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202211363B (en) | 2023-07-26 |
| EP4121083A1 (en) | 2023-01-25 |
| KR20230002361A (ko) | 2023-01-05 |
| CN115335072A (zh) | 2022-11-11 |
| JP2023518711A (ja) | 2023-05-08 |
| AU2021236662A1 (en) | 2022-11-10 |
| US20230381265A1 (en) | 2023-11-30 |
| WO2021188753A1 (en) | 2021-09-23 |
| US11986509B2 (en) | 2024-05-21 |
| US20210290723A1 (en) | 2021-09-23 |
| EP4121083A4 (en) | 2023-11-29 |
| IL296368A (en) | 2022-11-01 |
| CA3171225A1 (en) | 2021-09-23 |
| BR112022018654A2 (pt) | 2023-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550537A1 (en) | Oral formulations of kappa opioid receptor agonists | |
| AR058620A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| MX2024001201A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con agonistas de glp-1 para usarse en tratar enfermedades del higado graso. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| MX2021008247A (es) | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion. | |
| MX2015015589A (es) | Composiciones y metodos para el suministro de agentes activos hidrófobos. | |
| HK1176318A1 (en) | Injection device | |
| TW200738288A (en) | Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MX2022011527A (es) | Formulaciones de oligosacaridos de agonistas del receptor opioide kappa. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| MX2013014518A (es) | Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio. | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| WO2024102808A3 (en) | Compositions and methods for cns diseases |